Loading…
ATR Inhibitors in Platinum-Resistant Ovarian Cancer
Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatment method. Several targeted therapies, including t...
Saved in:
| Published in: | Cancers 2022-11, Vol.14 (23), p.5902 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c488t-179da0bf28694f28753eb82ad1a180efd9c491922e28dfdefaee79c9c5328b6a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c488t-179da0bf28694f28753eb82ad1a180efd9c491922e28dfdefaee79c9c5328b6a3 |
| container_end_page | |
| container_issue | 23 |
| container_start_page | 5902 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Li, Siyu Wang, Tao Fei, Xichang Zhang, Mingjun |
| description | Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatment method. Several targeted therapies, including those using bevacizumab and poly (ADP-ribose) polymerase inhibitor (PARPi), have been used to treat PROC. Ataxia telangiectasia and RAD3-Related Protein Kinase inhibitors (ATRi) have attracted attention as a promising class of targeted drugs that can regulate the cell cycle and influence homologous recombination (HR) repair. In recent years, many preclinical and clinical studies have demonstrated the efficacy of ATRis in PROC. This review focuses on the anticancer mechanism of ATRis and the progress of research on ATRis for PROC. |
| doi_str_mv | 10.3390/cancers14235902 |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9740197</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A745273103</galeid><sourcerecordid>A745273103</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-179da0bf28694f28753eb82ad1a180efd9c491922e28dfdefaee79c9c5328b6a3</originalsourceid><addsrcrecordid>eNptUV1rHSEQldCShNs8960s9KUvm6jjrvpSuFzSNhBICemzuO5sYtjVVHcD-ffxNt-hCo7omTNz5hDymdFDAE2PnA0OU2aCQ6Mp3yH7nEpet60WH17d98hBzte0LAAmW7lL9qAVWoKS-wTWF-fVSbjynZ9jypUP1e_Rzj4sU32O2efZhrk6u7XJ21Bt_lX8RD4Odsx48BhX5M-P44vNr_r07OfJZn1aO6HUXDOpe0u7gavSRDllA9gpbntmmaI49NoJzTTnyFU_9DhYRKmddg1w1bUWVuT7A-_N0k3YOwxzsqO5SX6y6c5E683bn-CvzGW8NVoKyorAFfn2SJDi3wXzbCafHY6jDRiXbHhpCRjwdgv9-g56HZcUiryCEqphAEq8oC7tiMaHIZa6bktq1lI0XAIrQ16Rw_-gyu5x8i4GHHx5f5Nw9JDgUsw54fCskVGztdq8s7pkfHk9mmf8k7FwD2Jso8A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2748513384</pqid></control><display><type>article</type><title>ATR Inhibitors in Platinum-Resistant Ovarian Cancer</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Li, Siyu ; Wang, Tao ; Fei, Xichang ; Zhang, Mingjun</creator><creatorcontrib>Li, Siyu ; Wang, Tao ; Fei, Xichang ; Zhang, Mingjun</creatorcontrib><description>Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatment method. Several targeted therapies, including those using bevacizumab and poly (ADP-ribose) polymerase inhibitor (PARPi), have been used to treat PROC. Ataxia telangiectasia and RAD3-Related Protein Kinase inhibitors (ATRi) have attracted attention as a promising class of targeted drugs that can regulate the cell cycle and influence homologous recombination (HR) repair. In recent years, many preclinical and clinical studies have demonstrated the efficacy of ATRis in PROC. This review focuses on the anticancer mechanism of ATRis and the progress of research on ATRis for PROC.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14235902</identifier><identifier>PMID: 36497387</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antigens ; Apoptosis ; Ataxia telangiectasia ; Ataxia telangiectasia mutated protein ; Bevacizumab ; Cancer therapies ; Cell cycle ; Chemical inhibitors ; Chemotherapy ; Clinical trials ; Collaboration ; Disease ; DNA damage ; Dosage and administration ; Drug delivery ; Drug therapy ; Gene expression ; Homologous recombination ; Immunotherapy ; Kinases ; Medical prognosis ; Mutation ; Ovarian cancer ; Palliative care ; Patients ; Platinum ; Prognosis ; Protein kinase inhibitors ; Proteins ; Radiation therapy ; Response rates ; Review ; Ribose ; Surgery ; Womens health</subject><ispartof>Cancers, 2022-11, Vol.14 (23), p.5902</ispartof><rights>COPYRIGHT 2022 MDPI AG</rights><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-179da0bf28694f28753eb82ad1a180efd9c491922e28dfdefaee79c9c5328b6a3</citedby><cites>FETCH-LOGICAL-c488t-179da0bf28694f28753eb82ad1a180efd9c491922e28dfdefaee79c9c5328b6a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2748513384/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2748513384?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,36994,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36497387$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Siyu</creatorcontrib><creatorcontrib>Wang, Tao</creatorcontrib><creatorcontrib>Fei, Xichang</creatorcontrib><creatorcontrib>Zhang, Mingjun</creatorcontrib><title>ATR Inhibitors in Platinum-Resistant Ovarian Cancer</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatment method. Several targeted therapies, including those using bevacizumab and poly (ADP-ribose) polymerase inhibitor (PARPi), have been used to treat PROC. Ataxia telangiectasia and RAD3-Related Protein Kinase inhibitors (ATRi) have attracted attention as a promising class of targeted drugs that can regulate the cell cycle and influence homologous recombination (HR) repair. In recent years, many preclinical and clinical studies have demonstrated the efficacy of ATRis in PROC. This review focuses on the anticancer mechanism of ATRis and the progress of research on ATRis for PROC.</description><subject>Antigens</subject><subject>Apoptosis</subject><subject>Ataxia telangiectasia</subject><subject>Ataxia telangiectasia mutated protein</subject><subject>Bevacizumab</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Chemical inhibitors</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Collaboration</subject><subject>Disease</subject><subject>DNA damage</subject><subject>Dosage and administration</subject><subject>Drug delivery</subject><subject>Drug therapy</subject><subject>Gene expression</subject><subject>Homologous recombination</subject><subject>Immunotherapy</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Mutation</subject><subject>Ovarian cancer</subject><subject>Palliative care</subject><subject>Patients</subject><subject>Platinum</subject><subject>Prognosis</subject><subject>Protein kinase inhibitors</subject><subject>Proteins</subject><subject>Radiation therapy</subject><subject>Response rates</subject><subject>Review</subject><subject>Ribose</subject><subject>Surgery</subject><subject>Womens health</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptUV1rHSEQldCShNs8960s9KUvm6jjrvpSuFzSNhBICemzuO5sYtjVVHcD-ffxNt-hCo7omTNz5hDymdFDAE2PnA0OU2aCQ6Mp3yH7nEpet60WH17d98hBzte0LAAmW7lL9qAVWoKS-wTWF-fVSbjynZ9jypUP1e_Rzj4sU32O2efZhrk6u7XJ21Bt_lX8RD4Odsx48BhX5M-P44vNr_r07OfJZn1aO6HUXDOpe0u7gavSRDllA9gpbntmmaI49NoJzTTnyFU_9DhYRKmddg1w1bUWVuT7A-_N0k3YOwxzsqO5SX6y6c5E683bn-CvzGW8NVoKyorAFfn2SJDi3wXzbCafHY6jDRiXbHhpCRjwdgv9-g56HZcUiryCEqphAEq8oC7tiMaHIZa6bktq1lI0XAIrQ16Rw_-gyu5x8i4GHHx5f5Nw9JDgUsw54fCskVGztdq8s7pkfHk9mmf8k7FwD2Jso8A</recordid><startdate>20221129</startdate><enddate>20221129</enddate><creator>Li, Siyu</creator><creator>Wang, Tao</creator><creator>Fei, Xichang</creator><creator>Zhang, Mingjun</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221129</creationdate><title>ATR Inhibitors in Platinum-Resistant Ovarian Cancer</title><author>Li, Siyu ; Wang, Tao ; Fei, Xichang ; Zhang, Mingjun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-179da0bf28694f28753eb82ad1a180efd9c491922e28dfdefaee79c9c5328b6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Apoptosis</topic><topic>Ataxia telangiectasia</topic><topic>Ataxia telangiectasia mutated protein</topic><topic>Bevacizumab</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Chemical inhibitors</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Collaboration</topic><topic>Disease</topic><topic>DNA damage</topic><topic>Dosage and administration</topic><topic>Drug delivery</topic><topic>Drug therapy</topic><topic>Gene expression</topic><topic>Homologous recombination</topic><topic>Immunotherapy</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Mutation</topic><topic>Ovarian cancer</topic><topic>Palliative care</topic><topic>Patients</topic><topic>Platinum</topic><topic>Prognosis</topic><topic>Protein kinase inhibitors</topic><topic>Proteins</topic><topic>Radiation therapy</topic><topic>Response rates</topic><topic>Review</topic><topic>Ribose</topic><topic>Surgery</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Siyu</creatorcontrib><creatorcontrib>Wang, Tao</creatorcontrib><creatorcontrib>Fei, Xichang</creatorcontrib><creatorcontrib>Zhang, Mingjun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Siyu</au><au>Wang, Tao</au><au>Fei, Xichang</au><au>Zhang, Mingjun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ATR Inhibitors in Platinum-Resistant Ovarian Cancer</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-11-29</date><risdate>2022</risdate><volume>14</volume><issue>23</issue><spage>5902</spage><pages>5902-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatment method. Several targeted therapies, including those using bevacizumab and poly (ADP-ribose) polymerase inhibitor (PARPi), have been used to treat PROC. Ataxia telangiectasia and RAD3-Related Protein Kinase inhibitors (ATRi) have attracted attention as a promising class of targeted drugs that can regulate the cell cycle and influence homologous recombination (HR) repair. In recent years, many preclinical and clinical studies have demonstrated the efficacy of ATRis in PROC. This review focuses on the anticancer mechanism of ATRis and the progress of research on ATRis for PROC.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36497387</pmid><doi>10.3390/cancers14235902</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-11, Vol.14 (23), p.5902 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9740197 |
| source | Publicly Available Content (ProQuest); PubMed Central |
| subjects | Antigens Apoptosis Ataxia telangiectasia Ataxia telangiectasia mutated protein Bevacizumab Cancer therapies Cell cycle Chemical inhibitors Chemotherapy Clinical trials Collaboration Disease DNA damage Dosage and administration Drug delivery Drug therapy Gene expression Homologous recombination Immunotherapy Kinases Medical prognosis Mutation Ovarian cancer Palliative care Patients Platinum Prognosis Protein kinase inhibitors Proteins Radiation therapy Response rates Review Ribose Surgery Womens health |
| title | ATR Inhibitors in Platinum-Resistant Ovarian Cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A46%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ATR%20Inhibitors%20in%20Platinum-Resistant%20Ovarian%20Cancer&rft.jtitle=Cancers&rft.au=Li,%20Siyu&rft.date=2022-11-29&rft.volume=14&rft.issue=23&rft.spage=5902&rft.pages=5902-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14235902&rft_dat=%3Cgale_pubme%3EA745273103%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c488t-179da0bf28694f28753eb82ad1a180efd9c491922e28dfdefaee79c9c5328b6a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2748513384&rft_id=info:pmid/36497387&rft_galeid=A745273103&rfr_iscdi=true |